Latest Conference Articles

Dr. Reckamp on Treatment Decisions in MET Exon 14–Mutated NSCLC

Karen Reckamp, MD, compares capmatinib and tepotinib, 2 drugs that are approved for the treatment of MET exon 14–mutated non–small cell lung cancer.

Oral SERDs Could Fulfill Unmet Need in ESR1-Mutant, ER-Positive Breast Cancer

Aditya Bardia, MD, MPH, discusses recent and ongoing trials evaluating oral SERDs in estrogen receptor–positive breast cancer, the effect of ESR1 mutations on treatment efficacy, and how the use of ctDNA continues to evolve across the breast cancer space.

HER2-Mutated NSCLC Treatment Evolves From Mainstay TKIs to Novel ADCs and Beyond

Antibody-drug conjugates have demonstrated substantial activity in patients with HER2-mutated non–small cell lung cancer, with fam-trastuzumab deruxtecan-nxki showcasing the strongest response rate and progression-free survival benefit to date.

Dr. Gandara on the Evaluation of Tumor Biomarkers in NSCLC

David R. Gandara, MD, discusses the evaluation of tumor biomarkers in non–small cell lung cancer.

Dr. Massarelli on Unmet Needs in EGFR Exon 20–Mutated NSCLC

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in EGFR exon 20–mutated non–small cell lung cancer.

Value of Biomarkers for Immunotherapy in Advanced NSCLC Continue to Evolve

Traditional predictive biomarkers for the efficacy of peri-operative immunotherapy for patients with advanced non–small cell lung cancer, such as PD-L1 expression, still hold value but newer biomarker candidates such as minimal residual disease are starting to make an impact.

Pathology Expert Unpacks the Future Role MPR and pCR in Neoadjuvant NSCLC Treatment

Ignacio I. Wistuba, MD, explains how major pathological response and pathological complete response should be interpreted and their role as clinical end points.

MRD Status Alone Is Not Necessarily Predictive of Response to Immunotherapy in NSCLC

Thought minimal residual disease can serve as an indicator for poor outcomes for patients with non–small cell lung cancer, it is not necessarily a predictor of response to immunotherapy.

P53-Mutated MCL Remains Difficult to Treat

Mutations in the p53 gene are associated with poor prognosis for patients with mantle cell lymphoma. Although modern regimens have improved outcomes, those treatments are associated with significant toxicity and, so far, have produced limited efficacy.

BiTEs, CAR T-Cell Therapy, and ADCs Offer Variety of Lymphoma Treatment Options, But Questions Remain

An influx of bispecific T-cell engagers, CAR T-cell therapies, and antibody-drug conjugates have revolutionized the treatment of hematologic malignancies; however, with several options in the sandbox, accessibility and unexplored clinical questions present challenges for optimal integration of these options into treatment.

ASCT No Longer Suitable for the Majority of Patients with DLBCL

Most patients with diffuse large B-cell lymphoma do not derive significant benefit from treatment with autologous stem cell transplantation and better therapeutic options are currently available for this population.

Zanubrutinib Displays Improved Efficacy Vs Orelabrutinib in Relapsed/Refractory CLL/SLL and MCL

Zanubrutinib demonstrated a significant improvement in progression-free survival compared with orelabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma or mantle cell lymphoma.

CDK4/6 Inhibitors Could Fill Treatment Void for Patients with HR+/HER2- Early Breast Cancer

Joyce O'Shaughnessy, MD, outlines the current role and ongoing research of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative early stage breast cancer.

Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL

CAR T-cell therapy, autologous stem cell transplant, and novel agents each have a role to play in the second-line management of patients with primary refractory diffuse large B-cell lymphoma, according to Jason Westin, MD, MS, FACP, and Laurie H. Sehn, MD, MPH.

Pooled Real-World Data Support Earlier Line Use of IRd in Relapsed/Refractory Multiple Myeloma

A pooled analysis of the INSIGHT MM, UVEA-IXA, and REMIX observational studies found that real-world outcomes with ixazomib/lenalidomide/dexamethasone were consistent with those reported in the TOURMAILINE-MM1 study.

Increased Treatment Efficacy in p53-Mutated MCL Remains Elusive

Tycel Jovelle Phillips, MD, outlines the reasons why p53-mutated mantle cell lymphoma is difficult to treat and discusses potential future directions for the treatment of this subgroup of patients.

Multidisciplinary Team Approach Is Ideal for irAE Management in Follicular Lymphoma

Immune checkpoint inhibitor therapy in relapsed follicular lymphoma can induce immune-related adverse events which can be difficult to diagnose and manage.

Adding Novel Agents to Established Chemotherapy Regimens Key to Expanding Frontline Treatment of Classic Hodgkin Lymphoma

Alison J. Moskowitz, MD, explains how the addition of novel agents to established chemotherapy regimens could further shift the frontline treatment paradigm for classic Hodgkin lymphoma.

Brentuximab Vedotin Boosts Survival in Adult and AYA Patients with Advanced Hodgkin Lymphoma

Ann S. LaCasce, MD, MMSC, explains how bretuximab vedotin has produced a survival benefit in patients with advanced classic Hodgkin lymphoma.

Dr. Kallam on the Role of BTK and PI3K Inhibitors in CNS Lymphoma

Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.

Rituximab Maintenance Therapy Continues to Provide Remission Benefit in MCL

Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.

Zanubrutinib Showcases Superior PFS Benefit Over BR in Treatment-Naïve CLL/SLL, Including High-Risk Subsets

Zanubrutinib was found to significantly improve progression-free survival over a doublet comprised of bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from cohort 1 of the phase 3 SEQUOIA trial.

CB-010 Exhibits Impressive Early Efficacy in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

The CAR T-cell therapy CB-010 displayed promising preliminary efficacy and safety results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma according to findings from the phase 1 ANTLER trial presented during the 2022 Pan Pacific Lymphoma Meeting.

Polatuzumab Vedotin Plus R-CHP Significantly Extends PFS in Untreated DLBCL

Polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, induced a 27% reduction in relative risk for disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.

Real-World Evidence On Shared Decision-Making Is Critical for Improving Patient Satisfaction in DLBCL

Integrating the lived experiences of patients with relapsed or refractory diffuse-large B-cell lymphoma into treatment-decision making should be a priority for practicing oncologists.

Pirtobrutinib Elicits 50% Response Rate in BTK-Pretreated MCL

Pirtobrutinib demonstrated potent antitumor activity and a low incidence of adverse effects in patients with BTK-pretreated and -naïve mantle cell lymphoma.

Zanubrutinib Represents Viable Treatment Option for Acalabrutinib-Intolerant B-cell Malignancies

Treatment with zanubrutinib maintained or improved response without an increase in acalabrutinib intolerance events in patients with previously treated B-cell malignancies.

CHOP-Based Combinations Represent Evolving Standard of Care in Frontline Treatment of PTCL

Neha Mehta-Shah, MD, MSCI, discusses frontline therapies in peripheral T-cell lymphoma, highlighting the current treatment landscape and the need to explore more treatment options in clinical trials.

BTK Inhibitor–Based Combinations May Improve the Efficacy of SOC Treatment in CNS Lymphoma

Avyakta Kallam, MBBS, discusses the benefits and shortcomings of the current standard of care in central nervous system lymphoma and expressed the importance of studying frontline targeted agents in this population.

Optimized Therapy Requires More Than Binary Understanding of HER2 Positivity in Metastatic Breast Cancer

Neratinib-based combinations, antibody-drug conjugates, and bispecific antibodies represent novel and effective treatment options for patients with pretreated HER2-mutant and HER2-low metastatic breast cancer, but the successful integration of these regimens into care will require further investigation into current definitions of HER2 positivity.